Distribution Rui Carrington, CEO of OCP Portugual, a Pharmaceutical distributor which has undergone a significant evolution over the years as part of an adaptation to the changing market trends in Portugal, outlines the history of the company, and offers insight into the ways in which local pharmacies can recover from their…
Generics João Madeira, General Manager of Mylan Portugal provides an overview of the state of generics in Portugal today, discussing structural issues related to Portugal’s low generic medicines penetration, ways to better promote healthcare savings, and Mylan’s own contributions to ensuring a sustainable marketplace in Portugal. Prior to Mylan, you worked…
Generics Hernâni Sério, General Manager of the Portuguese affiliate, Fresenius Kabi, discusses the challenges of the hospital market, as well as his company’s strategic positioning in a market with few competitors in the manufacturing and export business. How has Fresenius Kabi developed since the acquisition of Labesfal in 2005? This…
Generics Mario Martins, General Manager of Cegedim Portugal discusses the changes that his affiliate has made to adapt to the new realities of the Portuguese marketplace, and explains how a business diversification strategy helped the Company maintain a strong presence in a tough environment. In what ways have you redesigned…
medical tourism Joaquim Cunha, Executive Director of Health Cluster Portugal (HCP), emphasizes Portugal’s need to discover niches in which the country can excel and compete globally, while rebranding its image around the world. He also highlights the drivers behind cluster’s main initiatives: innovation, collaboration/coopetition and internationalization. What is Portugal’s number one…
R&D Servier Portugal’s general manager José Albino Mendes discusses how Portugal’s economic crisis provides real opportunities for growth, the potential for attracting talent in innovative research, and the affiliate’s recently opened international center for research. You have managed Servier Portugal for ten years. From your perspective, could you describe the evolution…
Country Report Our last report was in 2009-2010 when the “social emergency crisis” happened. What would you say have been the most important changes in the health system since that time? The main cause of the crisis was a drastic increase in the number of recobros (individuals asking to be reimbursed for…
Array The managing director of Brussels Invest & Export discusses Belgium’s unique attractiveness when it comes to the life sciences, and which countries and companies are interested in investing in the pharmaceutical sector in the country and why. After its creation in 2003, Invest in Brussels joined forces with Brussels…
India Dilip Surana of family-run Indian generics giant Micro Labs talks company performance, the evolution of the Indian pharma market, and strategy moving forward. Last year Micro Labs moved up in the rankings. How satisfied are you with the company’s performance in 2010? The company performed satisfactorily last year, showing good…
Fundacion ExportAR Fundacion Export.Ar was formed in 1993. What was the vision behind the foundation of the company and why was it formed at that specific time? Argentina understood that the country had to create an agency to promote exports. We were a closed economy, and Argentina was trying to become an…
See our Cookie Privacy Policy Here